


## Esthetics International Group

Recommendation:

**BUY**Stock Code: **5081**Bloomberg: **EIG MK**Price: **MYR0.87**12-Month Target Price: **MYR0.97**Date: **December 30, 2005****Board:** Main**Sector:** Trading / Services**GICS:** Consumer Staples / Personal Products**Market Capitalization:** MYR104.4 mln

**Summary:** Esthetics International Group (EIG) is the exclusive distributor of several brands of professional skincare and beauty products in Malaysia and parts of Asia, with the most well known brand being Dermalogica. EIG also provides professional skincare and beauty services via the operations of Leonard Drake and Belle Lina Skincare Centres in and around the Asian region. EIG was listed on the Main Board of Bursa Malaysia in March 2004.

**Analyst:** Hoe Lee Leng, CPA**Results Review & Earnings Outlook**

- EIG's 9MFY06's (Jan.) results were slightly below our expectations, accounting for 62% of our FY06 forecast versus our expectations of 65% (given the seasonality in earnings). The main reasons for this were: (i) start-up losses incurred by EIG's direct selling operations of MYR0.75mln and by its four new corporate outlets and two new consultation pods of MYR0.4mln; and (ii) an increase in the proportion of sales from product distribution versus services, which yield higher margins. EBIT margins fell to 15.6% in 9MFY06 from 19.5% in 9MFY05.
- EIG is changing its financial year-end from Jan. 31 to March 31, and we have adjusted our earnings forecasts to take this into account. We project EIG to record a net profit of MYR13.0 mln for FY06 (14 months to Mar.) (from MYR12.4 mln previously), while net profit for FY07 is projected at a lower MYR13.9 mln (from MYR14.3 mln), after taking into account higher depreciation charges for its new corporate office in Shah Alam, which costs MYR11 mln and would be completed by Feb. 2006. On an annualized basis, we have lowered our earnings projections by 4.5% for FY06 and by 3.1% for FY07.
- Post-revision, EIG's net profit will post a three-year CAGR of 9.2% (from 10.4%). Although start-up losses for new product launches and new outlet operations are likely to continue for the first six to 12 months of operations, we believe an expansion of its strong product distribution channels would help improve EBIT margins for its product trading division, especially from the franchising operations.

**Key Stock Statistics**

FY Mar.	Jan 2005	Mar 2006F
EPS (sen)	10.2	10.8
PER (x)	8.5	8.0
Dividend/Share (sen)	6.0	6.0
NTA/Share (MYR)	0.72	0.83
Book Value/Share (MYR)	0.72	0.83
Issued Capital (mln shares)	120.0	
52-week Share Price Range (MYR)	0.76 – 1.18	
Major Shareholders:	%	
Lim Yee Soon	25.1	
Melissa Chen	22.4	

**Recommendation & Investment Risks**

- We maintain our Buy recommendation on EIG with a 12-month target price of MYR0.97 (unchanged due to FY change and higher attributed discount). Our target price is based on a 35% discount (previously 30%) to 2006 market PER and includes the FY06 forecast net DPS of 4 sen. We attribute a higher discount for current weak market sentiment as well as for EIG's tight share liquidity and small free float of only 25%.
- We believe EIG's strong distribution system and established brand name via its Leonard Drake corporate outlets would enable it to complete its expansion plans successfully while remaining a step ahead of its competitors.
- Based on EIG's dividend policy, which is to distribute 30-50% of its net profit for at least the next two years, we forecast EIG's net dividend payout to average 40% p.a. over the next few years. This translates to net dividend yields of 5-6% p.a.
- Risks to our recommendation and target price include the extremely competitive environment EIG operates in, due to the ease of entry and low capital requirements. In addition, we believe EIG's overseas operations may be difficult to manage efficiently from Malaysia, given the diversity of cultures, operational structures and government regulations.

**Per Share Data**

FY Mar.	Jan. 03	Jan. 04	Jan. 05	Mar. 06F
Book Value (MYR)	NA	NA	0.72	0.83
Cash Flow (sen)	NA	NA	12.1	13.3
Earnings (sen)	NA	NA	10.2	10.8
Dividend (sen)	NA	NA	6.0	6.0
Payout Ratio (%)	NA	NA	42.4	40.0
PER (x)	NA	NA	8.5	8.0
P/Cash Flow (x)	NA	NA	7.2	6.5
P/Book Value (x)	NA	NA	1.2	1.0
Dividend Yield (%)	NA	NA	6.9	6.9
ROE (%)	NA	NA	14.1	13.0
Net Gearing (%)	NA	NA	0.0	0.0

All required disclosures appear on the last page of this report. Additional information is available upon request.

Redistribution or reproduction is prohibited without written permission. Copyright © 2005 The McGraw-Hill Companies, Inc.

Page 1 of 3

# Esthetics International Group

Recommendation: **BUY**

Stock Code: **5081**    Bloomberg: **EIG MK**    Price: **MYR0.87**    12-Month Target Price: **MYR0.97**    Date: **December 30, 2005**

## Quarterly Performance

FY Mar. / MYR mln	3QFY06	3QFY05	% Change
Revenue	25.9	20.7	24.7
Operating Profit (EBIT)	4.7	5.2	-9.7
Depreciation	NA	NA	NA
Net Interest Income / (Expense)	0.1	0.2	-50.2
Pretax Profit	4.8	5.4	-11.5
Net Profit	3.4	3.7	-8.0
Operating Margin (%)	18.1	24.9	-
Pretax Margin (%)	18.5	26.1	-
Net Margin (%)	13.3	18.0	-

Source: Company data

## Profit & Loss

FY Mar. / MYR mln	Jan. 04	Jan. 05	Mar. 06F	Mar. 07F
Revenue	NA	80.7	109.9	121.1
Operating Profit (EBIT)	NA	20.7	24.1	27.5
Depreciation	NA	2.3	3.0	4.0
Net Interest Income / (Expense)	NA	1.3	1.4	1.1
Pretax Profit	NA	17.7	18.6	20.0
Effective Tax Rate (%)	NA	30.8	30.0	30.0
Net Profit	NA	12.2	13.0	13.9
Operating Margin (%)	NA	25.7	21.9	22.7
Pretax Margin (%)	NA	22.0	16.9	16.5
Net Margin (%)	NA	15.2	11.8	11.5

Source: Company data, S&P Equity Research

**Standard & Poor's Equity Research Services**

Standard & Poor's Equity Research Services U.S. includes Standard & Poor's Investment Advisory Services LLC; Standard & Poor's Equity Research Services Europe includes Standard & Poor's LLC- London and Standard & Poor's AB (Sweden); Standard & Poor's Equity Research Services Asia includes Standard & Poor's LLC's offices in Hong Kong, Singapore and Tokyo, Standard & Poor's Malaysia Sdn Bhd and Standard & Poor's Information Services (Australia) Pty Ltd.

**Glossary**

**Strong Buy:** Total return is expected to outperform the total return of the KLCI or KL Emas Index respectively, by a wide margin over the coming 12 months, with shares rising in price on an absolute basis.

**Buy:** Total return is expected to outperform the total return of the KLCI or KL Emas Index respectively, over the coming 12 months, with shares rising in price on an absolute basis.

**Hold:** Total return is expected to closely approximate the total return of the KLCI or KL Emas Index respectively, over the coming 12 months with shares generally rising in price on an absolute basis.

**Sell:** Total return is expected to underperform the total return of the KLCI or KL Emas Index respectively, over the coming 12 months and share price is not anticipated to show a gain.

**Strong Sell:** Total return is expected to underperform the total return of the KLCI or KL Emas Index respectively, over the coming 12 months by a wide margin, with shares falling in price on an absolute basis.

**S&P 12 Month Target Price** – The S&P equity analyst's projection of the market price a given security will command 12 months hence, based on a combination of intrinsic, relative, and private market valuation metrics.

**Required Disclosures**

**All of the views expressed in this research report accurately reflect the research analyst's personal views regarding any and all of the subject securities or issuers. No part of analyst compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed in this research report.**

**Additional information is available upon request.**

**Other Disclosures**

This report has been prepared and issued by Standard & Poor's and/or one of its affiliates. In the United States, research reports are prepared by Standard & Poor's Investment Advisory Services LLC ("SPIAS"). In the United States, research reports are issued by Standard & Poor's ("S&P"), in the United Kingdom by Standard & Poor's LLC ("S&P LLC"), which is authorized and regulated by the Financial Services Authority; in Hong Kong by Standard & Poor's LLC which is regulated by the Hong Kong Securities Futures Commission, in Singapore by Standard & Poor's LLC, which is regulated by the Monetary Authority of Singapore; in Japan by Standard & Poor's LLC, which is regulated by the Kanto Financial Bureau; in Sweden by Standard & Poor's AB ("S&P AB"), in Malaysia by Standard & Poor's Malaysia Sdn Bhd ("S&PM") which is regulated by the Securities Commission and in Australia by Standard & Poor's Information Services (Australia) Pty Ltd ("SPIS") which is regulated by the Australian Securities & Investments Commission.

The research and analytical services performed by SPIAS, S&P LLC, S&P AB, S&PM and SPIS are each conducted separately from any other analytical activity of Standard & Poor's.

**CMDF-Bursa Research Scheme ("CBRS")**

This report has been prepared by S&PM for purposes of CBRS administered by Bursa Malaysia Berhad, independent from any influence from CBRS or the subject company. S&P will receive total compensation of MYR15,000 each year for each company covered by it under CBRS. For more information about CBRS, please visit Bursa Malaysia's website at:

<http://www.bursamalaysia.com/website/listing/cbrs.htm>

**Disclaimers**

This material is based upon information that we consider to be reliable, but neither S&P nor its affiliates warrant its completeness, accuracy or adequacy and it should not be relied upon as such. With respect to reports issued by S&P LLC-Japan and in the case of inconsistencies between the English and Japanese version of a report, the English version prevails. Neither S&P LLC nor S&P guarantees the accuracy of the translation. Assumptions, opinions and estimates constitute our judgment as of the date of this material and are subject to change without notice. Neither S&P nor its affiliates are responsible for any errors or omissions or for results obtained from the use of this information. Past performance is not necessarily indicative of future results.

This material is not intended as an offer or solicitation for the purchase or sale of any security or other financial instrument. Securities, financial instruments or strategies mentioned herein may not be suitable for all investors. Any opinions expressed herein are given in good faith, are subject to change without notice, and are only correct as of the stated date of their issue. Prices, values, or income from any securities or investments mentioned in this report may fall against the interests of the investor and the investor may get back less than the amount invested. Where an investment is described as being likely to yield income, please note that the amount of income that the investor will receive from such an investment may fluctuate. Where an investment or security is denominated in a different currency to the investor's currency of reference, changes in rates of exchange may have an adverse effect on the value, price or income of or from that investment to the investor. The information contained in this report does not constitute advice on the tax consequences of making any particular investment decision. This material does not take into account your particular investment objectives, financial situations or needs and is not intended as a recommendation of particular securities, financial instruments or strategies to you. Before acting on any recommendation in this material, you should consider whether it is suitable for your particular circumstances and, if necessary, seek professional advice.

For residents of the U.K. This report is only directed at and should only be relied on by persons outside of the United Kingdom or persons who are inside the United Kingdom and who have professional experience in matters relating to investments or who are high net worth persons, as defined in Article 19(5) or Article 49(2) (a) to (d) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2001, respectively.

For residents of Malaysia. All queries in relation to this report should be referred to: Alexander Chia, ACA  
Hoe Lee Leng, CPA